Key Highlights
- Net Revenue was USD 14.84 million, against an estimate of USD 13.27 million.
- Net loss per share was USD 0.20, narrower than the USD 0.26 loss expected.
- Gross profit rose to USD 9.44 million from USD 9.19 million.
- Cash and cash equivalents were USD 25.49 million at September 30, 2026.
Aytu BioPharma (NASDAQ:AYTU) reported net revenue of USD 14.84 million for the first quarter of fiscal 2027, which ended September 30, 2026. That was up from USD 13.89 million a year earlier and ahead of the estimate of USD 13.27 million. Basic and diluted net loss per share was USD 0.20, against an estimate of a USD 0.26 loss.
The quarter ended in a net loss of USD 3.88 million, a Reversal from Net Income of USD 1.97 million in the prior-year quarter. For that earlier period, diluted net loss per share was USD 0.08, and basic net income per share was USD 0.21.
Gross Profit and Spending
Cost of goods sold was USD 5.41 million, compared with USD 4.70 million, which left Gross Profit at USD 9.44 million, compared with USD 9.19 million. Selling and Marketing expenses climbed to USD 6.62 million from USD 5.32 million, and general and administrative expenses to USD 5.99 million from USD 4.92 million. Amortization of intangible Assets was USD 761 thousand, compared with USD 444 thousand.
Total operating expenses were USD 13.37 million, compared with USD 10.69 million, and the loss from operations was USD 3.93 million, compared with USD 1.50 million. Other income, net, was USD 180 thousand, interest expense was USD 408 thousand, compared with USD 516 thousand, and the gain on derivative Warrant liabilities was USD 276 thousand, compared with USD 3.78 million.
From Pre-Tax Loss to Share Data
The loss before income tax expense was USD 3.88 million, compared with income of USD 1.97 million, and no income tax expense was recorded. Basic weighted average common shares outstanding were 19,325,285, compared with 9,441,073, and diluted weighted average common shares outstanding were 19,325,285, compared with 19,476,635.
The statement of stockholders' Equity shows 10,728,208 shares of common stock at June 30, 2026, with 140,000 shares added during the quarter through stock-based compensation expense and the issuance of restricted stock, net of forfeitures. Total stockholders' equity was USD 35.27 million at June 30, 2026.
Cash and the Balance Sheet
Cash and cash equivalents were USD 25.49 million at September 30, 2026, compared with USD 26.31 million at June 30, 2026, and net cash used in Operating Activities for the quarter was USD 0.3 million. Accounts receivable, net, fell to USD 20.33 million from USD 22.78 million, and inventories to USD 6.02 million from USD 6.86 million.
Total assets were USD 99.17 million, compared with USD 105.01 million, and total current liabilities were USD 53.33 million, compared with USD 54.66 million. Total liabilities were USD 67.61 million, compared with USD 69.73 million, and debt, net of current portion, was USD 8.65 million, compared with USD 9.10 million.






Please wait processing your request...